Unknown

Dataset Information

0

Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.

ABSTRACT:

SUBMITTER: Matsubara N 

PROVIDER: S-EPMC6828099 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.

Matsubara Nobuaki N   Mukai Hirofumi H   Hosono Ako A   Onomura Mai M   Sasaki Masaoki M   Yajima Yoko Y   Hashizume Kensei K   Yasuda Masanobu M   Uemura Miho M   Zurth Christian C  

Cancer chemotherapy and pharmacology 20171201 6

Similar Datasets

Unknown Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
| S-EPMC5686265 | biostudies-literature
Unknown ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
| S-EPMC4673554 | biostudies-literature
Unknown Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
| S-EPMC4490394 | biostudies-literature
Unknown An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
| S-EPMC6861345 | biostudies-literature
Unknown Comparative real-world study of apalutamide and darolutamide in Japanese patients with non-metastatic castration-resistant prostate cancer.
| S-EPMC12465178 | biostudies-literature
Unknown Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer.
| S-EPMC6958984 | biostudies-literature
Unknown Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer.
| S-EPMC12230269 | biostudies-literature
Unknown Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
| S-EPMC5041979 | biostudies-literature
Unknown Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
| S-EPMC6766977 | biostudies-literature
Unknown Darolutamide For Castration-Resistant Prostate Cancer.
| S-EPMC6816030 | biostudies-literature